An uMbrella Study of BIomarker-driven Targeted Therapy In Patients With Platinum-resistant Recurrent OvariaN Cancer(AMBITION)

NCT03699449 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

104

Enrollment

OTHER

Sponsor class

Conditions

Platinum-resistant Recurrent Ovarian Cancer

Interventions

DRUG: olaparib+cediranib combination therapy
DRUG: durvalumab + olaparib combination therapy
DRUG: durvalumab + chemotherapy treatment
DRUG: durvalumab + tremelimumab + chemotherapy treatment
DRUG: durvalumab + tremelimumab + paclitaxel treatment
DRUG: durvalumab +chemotherapy treatment

Sponsor

Yonsei University

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]